Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Bicine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.65 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.65 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.65 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.65 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.65 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.65 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.65 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.65 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.60 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.33 |
| ▸ | CA2 known ✓ | P00918 | 9/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicine SCHEMBL34161 | 0.97 | ALOX15 (0.68) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL177696 | 0.97 | ALOX15 (0.68) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL30968399 | 0.94 | TDP1 (0.65) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL20471950 | 0.94 | ALOX15 (0.65) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL30489348 | 0.94 | ALOX15 (0.65) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL5065705 | 0.94 | ALOX15 (0.65) | ALOX15KDM4ETSHRTDP1BLM | |
| SCHEMBL8968107 | 0.94 | TDP1 (0.74) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL3981657 | 0.94 | ALOX15 (0.65) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL5883443 | 0.94 | ALOX15 (0.65) | ALOX15KDM4ETSHRTDP1BLM | |
| Bicine SCHEMBL1747701 | 0.94 | ALOX15 (0.65) | ALOX15KDM4ETSHRTDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122076675-A | Systems and methods for delivering therapeutic agents | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260002930-A1 | BIOMARKERS FOR ALLERGEN IMMUNOTHERAPY | UNIV MONASH (AU) | 2026-01-01 | — | — | US | disclosed |
| US-20250163394-A1 | Mutant Cpf1 Endonucleases | UNIVERSITY OF COPENHAGEN (DK) | 2025-05-22 | — | — | US | disclosed |
| CN-114040760-B | Irreversible inhibitors of MENIN-MLL interactions | 拜欧米富士恩公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119841834-A | Irreversible inhibitors of MENIN-MLL interactions | 拜欧米富士恩公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4533085-A1 | BIOMARKERS FOR ALLERGEN IMMUNOTHERAPY | Monash University (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119585256-A | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119365493-A | Anti-CD 84 antibodies and uses thereof | 希望之城公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12152257-B2 | Mutant CPF1 endonucleases | UNIVERSITY OF COPENHAGEN (DK) | 2024-11-26 | — | — | US | disclosed |
| US-20240384319-A1 | Synthesis of Oligonucleotides | THE UNIVERSITY OF MANCHESTER (GB) | 2024-11-21 | — | — | US | disclosed |
| EP-1998752-A2 | POLYLACTIDE NANOPARTICLES | LTS LOHMANN Therapie-Systeme AG (DE) | 2008-12-10 | — | — | EP | disclosed |
| US-7400979-B2 | Kinase inhibitors; genetic engineering | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2007110152-A2 | POLYLACTIDE NANOPARTICLES | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2007-10-04 | — | — | WO | disclosed |
| US-4791055-A | ENZYME-CLEAVABLE BONDS | MILES INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4629688-A | CLINICAL ANALYSIS | MILES LABORATORIES, INC. (US) | 1986-12-16 | — | — | US | disclosed |
| US-4492751-A | Heterogenous specific binding assay employing an enzyme substrate as label | MILES LABORATORIES, INC. (US) | 1985-01-08 | — | — | US | disclosed |
| US-4383031-A | LIGANDS; IMMUNOASSAY; SIMPLIFICATION; DIAGNOSIS/MEDICAL/ | MILES LABORATORIES, INC. (US) | 1983-05-10 | — | — | US | disclosed |
| US-4380580-A | COUPLING, LABELS | MILES LABORATORIES, INC. (US) | 1983-04-19 | — | — | US | disclosed |
| US-4318980-A | Heterogenous specific binding assay employing a cycling reactant as label | MILES LABORATORIES, INC. (US) | 1982-03-09 | — | — | US | disclosed |
| US-4230797-A | NUCLEOTIDE | MILES LABORATORIES, INC. (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002930-A1 | BIOMARKERS FOR ALLERGEN IMMUNOTHERAPY | CD22, IL2RA, FCGR3B | CHRM2 1032/4885ADRA2A 807/4885DRD1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.